Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    FDA_Warning_Letters, Import_Alerts_&_EU_Non-Compliances_in_2019
    X

    Find Ophthalmology Drugs in Phase I Clinical Development

    A collaboration with SCORR Marketing

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    Country filter
      News Type filter
        Company filter
          Product Type filter
            Deal Size filter
              refresh

              Product Type

              Companies

              Ocular Therapeutix

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              EYEFORPHARMA

              Participation Not Confirmed

              Update your events

              Ocular Therapeutix Provides Update on Interim Data from the OTX-TKI Phase 1 Clinical Trial

              Contact the Supplier

              Lead Product(s): OTX-TKI

              Therapeutic Area: Ophthalmology

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 03, 2020

              Details:

              Two cohorts of six subjects each have been enrolled, a lower dose cohort of 200 ?g and a higher dose cohort of 400 ?g.

              Aerpio Pharmaceuticals

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              EYEFORPHARMA

              Participation Not Confirmed

              Update your events

              Aerpio Pharmaceuticals Presents Data from Fifth Patient Cohort

              Contact the Supplier

              Lead Product(s): Razuprotafib,Prostaglandin

              Therapeutic Area: Ophthalmology

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 10, 2020

              Details:

              The Phase 1b trial is a randomized, double-masked study designed to assess increasing concentrations of AKB-9778 dosed topically as eye drops.

              Adverum Biotechnologies

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              EYEFORPHARMA

              Participation Not Confirmed

              Update your events

              Adverum Biotechnologies Unveils Interim Data from OPTIC Trial

              Contact the Supplier

              Lead Product(s): Aflibercept

              Therapeutic Area: Ophthalmology

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 08, 2020

              Details:

              ADVM-022 demonstrated a robust efficacy signal and evidence of a dose response. In both cohorts combined, 10 of 12 (83%) patients remain rescue-injection-free.

              Oxurion NV

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              BELGIUM Belgium

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              EYEFORPHARMA

              Participation Not Confirmed

              Update your events

              Additional Topline Data from Positive Phase 1 Trial with THR-687

              Contact the Supplier

              Lead Product(s): THR-687

              Therapeutic Area: Ophthalmology

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 05, 2020

              Details:

              THR-687 is expected to enter a Phase 2 clinical trial in H2 2020. Positive topline results in a Phase 1 clinical study assessing it as a treatment for DME were announced in January 2020.

              Adverum Biotechnologies

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              EYEFORPHARMA

              Participation Not Confirmed

              Update your events

              Adverum Biotechnologies to Present Additional Data from the OPTIC Phase 1 Trial with ADVM-022 Intravitreal Gene Therapy in Wet AMD at the An...

              Contact the Supplier

              Lead Product(s): Aflibercept

              Therapeutic Area: Ophthalmology

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 28, 2020

              Details:

              Adverum Biotechnologies is conducting a phase1 study of Intravitreal gene therapy with ADVM-022 for Neovascular AMD (OPTIC Trial).

              Adverum Biotechnologies

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              EYEFORPHARMA

              Participation Not Confirmed

              Update your events

              Adverum Biotechnologies Reports Continued Momentum with OPTIC Trial for ADVM-022 Intravitreal Gene Therapy in Wet AMD and Provides 2020 Outl...

              Contact the Supplier

              Lead Product(s): Aflibercept

              Therapeutic Area: Ophthalmology

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 12, 2020

              Details:

              OPTIC phase 1 trial progressing with plans to complete patient dosing in cohort three, begin enrollment in cohort four in 1Q20. IND application planned for ADVM-022 in diabetic retinopathy in 1H20.

              Gemini Therapeutics

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              EYEFORPHARMA

              Participation Not Confirmed

              Update your events

              Gemini Therapeutics Enrolls First Patient in Phase 1 Study of GEM103 for Dry Age-related Macular Degeneration

              Contact the Supplier

              Lead Product(s): GEM103

              Therapeutic Area: Ophthalmology

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 09, 2020

              Details:

              The company looking forward to topline data from this study and the potential to initiate a Phase 2 study supported by the CLARITY natural history study data.

              Aerpio Pharmaceuticals

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              EYEFORPHARMA

              Participation Not Confirmed

              Update your events

              Topical Ocular Formulation of Aerpio Pharmaceutical’s AKB-9778 Product Candidate Produced IOP Lowering with Minimal Hyperemia When Combine...

              Contact the Supplier

              Lead Product(s): Razuprotafib,Prostaglandin

              Therapeutic Area: Ophthalmology

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 08, 2020

              Details:

              Topical ocular administration of AKB-9778 was well tolerated over seven days in cohort 5.

              PharmaCompass__DigitalAd